Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rika Wakao

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Frontiers in Medicine|May 4, 2023
<i>In vivo</i> CAR T cells and targeted gene delivery: A theme for the Pharmaceuticals and Medical Devices Agency Science Board to addressRika Wakao, Ai Fukaya-Shiba
Environmental Health and Preventive Medicine|March 25, 2011
Constitutively active Stat5A and Stat5B promote adipogenesisHiroshi Wakao, Rika Wakao, Atsushi Oda, et al.
Frontiers in Immunology|December 19, 2017
Mucosal-Associated Invariant T Cells in Regenerative MedicineHiroshi Wakao, Chie Sugimoto, Shinzo Kimura, et al.
BMC Health Services Research|October 27, 2022
Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in JapanShinobu Uzu, Jun Sato, Rika Wakao, et al.
Clinical and Translational Science|June 19, 2026
Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMATakahiro Handa, Arata Tanaka, Mayumi Shikano, et al.
Clinical Pharmacology and Therapeutics|January 20, 2021
PMDA's Vision for Horizon Scanning of Emerging Technologies Potentially Relevant to the Development of New Medical Products: The Regulatory ChallengeMasafumi Shimokawa, Daisaku Sato, Rika Wakao, et al.
British Journal of Clinical Pharmacology|September 16, 2021
Pharmaceuticals and Medical Devices Agency's horizon scanning and the Science Board: Cooperation toward extracellular vesicle-based productsAi Fukaya-Shiba, Masafumi Shimokawa, Hajime Sasaki, et al.
Drug Safety|April 10, 2021
The Use of Subgroup Disproportionality Analyses to Explore the Sensitivity of a Global Database of Individual Case Safety Reports to Known Pharmacogenomic Risk Variants Common in JapanRika Wakao, Ingrid M Lönnstedt, Yasunori Aoki, et al.
Frontiers in Medicine|October 28, 2021
Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell ImmunityAi Fukaya-Shiba, Kouhei Otsuka, Hajime Sasaki, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 8, 2008
In vitro induction of natural killer T cells from embryonic stem cells prepared using somatic cell nuclear transferHiroshi Wakao, Rika Wakao, Sakura Sakata, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Frontiers in Medicine|May 4, 2023
<i>In vivo</i> CAR T cells and targeted gene delivery: A theme for the Pharmaceuticals and Medical Devices Agency Science Board to addressRika Wakao, Ai Fukaya-Shiba
Environmental Health and Preventive Medicine|March 25, 2011
Constitutively active Stat5A and Stat5B promote adipogenesisHiroshi Wakao, Rika Wakao, Atsushi Oda, et al.
Frontiers in Immunology|December 19, 2017
Mucosal-Associated Invariant T Cells in Regenerative MedicineHiroshi Wakao, Chie Sugimoto, Shinzo Kimura, et al.
BMC Health Services Research|October 27, 2022
Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in JapanShinobu Uzu, Jun Sato, Rika Wakao, et al.
Clinical and Translational Science|June 19, 2026
Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMATakahiro Handa, Arata Tanaka, Mayumi Shikano, et al.
Clinical Pharmacology and Therapeutics|January 20, 2021
PMDA's Vision for Horizon Scanning of Emerging Technologies Potentially Relevant to the Development of New Medical Products: The Regulatory ChallengeMasafumi Shimokawa, Daisaku Sato, Rika Wakao, et al.
British Journal of Clinical Pharmacology|September 16, 2021
Pharmaceuticals and Medical Devices Agency's horizon scanning and the Science Board: Cooperation toward extracellular vesicle-based productsAi Fukaya-Shiba, Masafumi Shimokawa, Hajime Sasaki, et al.
Drug Safety|April 10, 2021
The Use of Subgroup Disproportionality Analyses to Explore the Sensitivity of a Global Database of Individual Case Safety Reports to Known Pharmacogenomic Risk Variants Common in JapanRika Wakao, Ingrid M Lönnstedt, Yasunori Aoki, et al.
Frontiers in Medicine|October 28, 2021
Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell ImmunityAi Fukaya-Shiba, Kouhei Otsuka, Hajime Sasaki, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 8, 2008
In vitro induction of natural killer T cells from embryonic stem cells prepared using somatic cell nuclear transferHiroshi Wakao, Rika Wakao, Sakura Sakata, et al.
Pageof 2